Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-05-2010 | Original Paper

Vascular endothelial growth factor and endoglin expression in colorectal cancer

Authors: Konstantinos Dassoulas, Maria Gazouli, George Theodoropoulos, Zoi Christoni, Spyros Rizos, Adamantia Zisi-Serbetzoglou, Chrissa Glava, Theodoros Karantanos, Christos Klonaris, Petros Karakitsos

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2010

Abstract

Purpose and methods

Vascular endothelial growth factor (VEGF) overexpression has been associated with advanced stage and poor survival in several cancers. Additionally, endoglin was proposed as a marker of neovascularization in solid malignancies. The aim of this study was to evaluate the association between the VEGF and endoglin expression in colorectal carcinoma patients, as well as to correlate the VEGF and endoglin expression with standard parameters, to define their potential prognostic role. VEGF and endoglin expression were evaluated in 99 unrelated patients with colorectal cancer using immunohistochemistry.

Results

Vascular endothelial growth factor and endoglobin expression were positively interrelated. No significant correlation of VEGF and endoglin expression with clinicopathological parameters was observed in our cases. The Kaplan–Meier survival curves have demonstrated a clear association of cancer-specific overall survival with high VEGF, as well as high endoglin expression.

Conclusion

Our results support that VEGF and endoglin act as two valuable indicators of prognosis.

Bossi P, Viale G, Lee AK, Alfano R, Coggi G, Bosari S (1995) Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55:5049–5053PubMed

Chung YS, Maeda K, Sowa M (1996) Prognostic value of angiogenesis in gastrointestinal tumors. Eur J Cancer 32A:2501–2505CrossRefPubMed

Couvelard A, Paraf F, Gratio V, Scoazec JY, Hénin D, Degott C, Fléjou JF (2000) Angiogenesis in the neoplastic sequence of Barrett’s esophagus: correlation with VEGF expression. J Pathol 192:14–18CrossRefPubMed

Du JR, Jiang Y, Zhang YM, Fu Y (2003) Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinoma. World J Gastroenterol 9:1604–1606PubMed

Duff SE, Li C, Garland JM, Kumar S (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J17:984–992CrossRef

Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803CrossRefPubMed

Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6CrossRefPubMed

Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, Volant A, Pera M (2004) p53 and VEGF expression are independent predictors of tumor recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206–215CrossRefPubMed

Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB (1995) Tumor angiogenesis as predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222:695–699CrossRefPubMed

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G, Försti A (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653CrossRefPubMed

Kang SM, Maeda K, Onoda N (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 74:502–507CrossRefPubMed

Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G, Tahara E (1998) Significance of vessel count and vascular endothelial growth factor in human esophageal carcinoma. Clin Cancer Res 4:2195–2200PubMed

Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36:748–753CrossRefPubMed

Los M, Roodhart JML, Voist EE (2007) Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12:443–450CrossRefPubMed

Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O (2006) Enoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. Virchows Arch 448:127–134CrossRefPubMed

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22PubMed

Nikiteas N, Tzanakis N, Theodoropoulos G, Atsaves V, Christoni Z, Karakitsos P, Lazaris AC, Papachristodoulou A, Klonaris C, Gazouli M (2007) Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 10:12–17CrossRefPubMed

Pietra N, Sarli L, Caruana P, Cabras A, Costi R, Gobbi S, Bordi C, Peracchia A (2000) Is tumor angiogenesis a prognostic factor in patients with colorectal cancer and no involved nodes? Eur J Surg 166:552–556CrossRefPubMed

Polverini PJ, Leibovich SJ (1984) Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 51:635–642PubMed

Saad RS, Jasnosz KM, Silverman JF (2003) Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol 22:248–253CrossRefPubMed

Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17:197–203CrossRefPubMed

Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB (1994) Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 37:921–926CrossRefPubMed

Scon BK, Matsuno F, Haruta Y, Kondo M, Barcos M (1997) Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3:1031–1044

Takahashi Y, Tucker SL, Kitadai Y (1997) Vessel counts and expression of vascular endothelial growth factors as prognostic factors in node-negative colon cancer. Arch Surg 132:541–546PubMed

Wang JM, Kumar S, Pye D, Haboubi N, al-Nakib L (1994) Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 86:386–388CrossRefPubMed

Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9–19PubMed

Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef

Wilkstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51:268–275CrossRef

Yamamori M, Sakaeda T, Nakamura T, Okamura N, Tamura T, Aoyama N, Kamigaki T, Ohno M, Shirakawa T, Gotoh A, Kuroda Y, Matsuo M, Kasuga M, Okumura K (2004) Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 325:144–150CrossRefPubMed

Yu JX, Zhang XT, Liao YQ, Zhang QY, Chen H, Lin M, Kumar S (2003) Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol 9:2866–2869PubMed

Title: Vascular endothelial growth factor and endoglin expression in colorectal cancer
Authors: Konstantinos Dassoulas
Maria Gazouli
George Theodoropoulos
Zoi Christoni
Spyros Rizos
Adamantia Zisi-Serbetzoglou
Chrissa Glava
Theodoros Karantanos
Christos Klonaris
Petros Karakitsos
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 5/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0709-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Vascular endothelial growth factor and endoglin expression in colorectal cancer

Abstract

Purpose and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2010

Genetic and protein changes of E-cadherin in meningiomas

Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma

Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page